HCV genotype matching between donor and recipient

HCV genotype matching between donor and recipient is a risk-management strategy developed for kidney transplantation from HCV-positive donors into recipients who already have HCV infection. Its importance rests on a clinically consequential distinction: HCV antibodies do not confer immunity, and an HCV-positive recipient may still acquire a new infection or become superinfected with a different viral genotype. Genotype matching therefore seeks to avoid adding a biologically distinct strain at transplantation, while acknowledging that the available evidence does not establish complete protection.

Biological Basis and Clinical Setting

HCV-positive donor kidneys became an important question because organ shortage makes the routine disposal of potentially usable kidneys difficult to justify. Early transplantation experience showed that HCV could be transmitted through kidney transplantation, with reported transmission probabilities ranging from 14% to 100% across series. The variability reflected differences in donor viral load, strain infectivity, preservation solution volume, preservation method, and diagnostic testing. These findings created a practical distinction between HCV-negative recipients, for whom kidneys from HCV-positive donors were generally considered inappropriate, and HCV-positive recipients, for whom transplantation could shorten time on the waiting list but still carried transmission risks.

An HCV-positive recipient is not necessarily protected merely because anti-HCV antibodies are present. Antibody positivity does not establish active viremia and does not function as sterilizing immunity. Consequently, transplantation from an HCV-positive donor can expose an already infected recipient to an additional viral population. The possibility of superinfection is especially relevant when the donor and recipient carry different genotypes, because the recipient’s existing infection may not neutralize the incoming strain.

Evidence for Superinfection Risk

Experimental evidence supports the concern that prior infection does not reliably prevent reinfection. In a post-transfusion HCV infection model involving chimpanzees, pre-existing infection failed to protect against reinfection with either a different genotype or, in some circumstances, the same genotype. Clinical transplant evidence points in the same direction: kidney transplant recipients with baseline HCV infection are not considered immune to superinfection with a new genotype.

The clinical consequences are not uniform. Mixed infection has not been associated with increased mortality in the evidence summarized by the source, but at least one report described severe liver disease after an HCV-positive kidney was transplanted into an HCV-positive recipient whose baseline infection differed from the donor’s, specifically a genotype 1-to-genotype 2 transmission. This contrast is central to the rationale for matching: the strategy is not based on the assumption that every genotype mismatch will cause severe disease, but on the possibility that a mismatch can produce a more hazardous clinical course in an individual recipient.

Matching as an Allocation Strategy

The proposed approach is straightforward in principle: when an HCV-positive kidney is offered to an HCV-positive recipient, the donor and recipient should, if possible, carry the same HCV genotype. The source identifies this as a way to increase the safety of using HCV-positive kidneys, because it may reduce exposure to a distinct strain and thereby lower the theoretical risk of superinfection with clinically important consequences.

Genotype matching is not presented as an absolute requirement or a proven guarantee. Its practical limitation is the time constraint inherent in organ transplantation. Donor testing, recipient assessment, organ allocation, and the need to make a timely decision may leave insufficient time to obtain and interpret genotype information before the kidney must be accepted or declined. Thus, matching may improve risk selection when results are available, but it cannot by itself resolve the larger allocation problem.

The evidence base also has important gaps. In a major published experience, genotype information was unavailable for both donors and recipients, preventing a reliable assessment of how often superinfection occurred and what clinical effects it produced. The absence of systematic genotype data means that the recommendation is biologically plausible and clinically prudent, but not supported by a definitive comparative trial demonstrating improved graft survival, patient survival, or liver outcomes.

Relationship to Other Safeguards

Genotype matching belongs within a broader set of measures intended to make transplantation from HCV-positive donors safer. Nucleic acid testing of donors has only recently been suggested in the cited discussion, and missing donor HCV RNA information remains another limitation of the evidence. Nevertheless, knowledge of donor RNA status was not expected to overturn the proposed allocation strategy. The central concern remains that serologic status alone cannot describe active infection or eliminate the possibility of transmission and superinfection.

Other measures address different parts of the same risk. Pulsatile perfusion has been reported to reduce the HCV viral load in HCV-positive kidneys, potentially lowering transmission, although the findings had not been reproduced in more recent studies. Pretransplant antiviral treatment aimed at achieving a sustained virological response may also reduce certain post-transplant complications, including HCV-related glomerular disease, but it is not compatible with deliberately allocating an HCV-positive kidney to a recipient whose infection has been cleared. Interferon treatment is prolonged, can produce substantial adverse events, has a meaningful nonresponse rate, may require removal from the waiting list, and is not universally affordable. For some HCV RNA-positive patients, transplantation with an HCV-positive kidney may therefore remain more favorable than continuing dialysis, particularly when treatment is refused, unsuccessful, withdrawn, or unsuitable.

Limits and Significance

The value of HCV genotype matching is ultimately shaped by a conflict between virological caution and the scarcity of kidneys. HCV-positive kidneys are more likely to be discarded than HCV-negative kidneys; one analysis found that they were discarded 2.60 times as often. At the same time, the number of available organs remains far below the number of patients waiting for transplantation, and prolonged dialysis carries its own burden. A strategy that treats every HCV-positive kidney as unusable would protect against one category of transmission while converting a scarce therapeutic resource into waste.

Genotype matching offers a way to make that compromise more discriminating. It recognizes that an HCV-positive recipient may accept a meaningful transplant opportunity without being biologically shielded from a donor strain. The strategy therefore converts genotype from a descriptive laboratory label into an allocation variable: a piece of molecular information that can influence whom an organ is offered to, how risk is explained, and whether a potentially usable kidney is transplanted. Its promise is real but bounded. Until donor and recipient RNA status, genotypes, liver histology, superinfection rates, and long-term clinical outcomes are measured systematically, matching should be understood as a reasoned risk-reduction measure rather than a definitive solution.